Puromycin dihydrochloride (CL13900 dihydrochloride) is a cinnamamide adenosine antibiotic and an inhibitor of protein synthesis. Puromycin dihydrochloride inhibits protein synthesis by binding to RNA and has antitumor and antitrypanosomal activity.

METHODS: Human hepatocellular carcinoma cells, HepG2, and primary rat hepatocytes, PRH, were treated with Puromycin dihydrochloride (0-300 µmol/L) for 72 h, and cell growth inhibition was detected by MTT.
RESULTS: Puromycin dihydrochloride dose-dependently inhibited the growth of HepG2 and PRH cells, with IC50s of 1600 μmol/L and 2000 nmol/L, respectively.[1]
METHODS: Human breast cancer cells MDA-MB-231 and MDA-MB-436 were transfected with shRNAs-Puro lentivirus, and after 24 h, the transfected cells were cultured in new medium containing Puromycin dihydrochloride (1 μg/ml) for about 12 days, and then the cells were screened for the success of transfection.
RESULTS: Puromycin dihydrochloride screened the lentivirally transfected cells successfully. [2]
METHODS: Cells transfected with lentivirus were cultured in medium supplemented with Puromycin dihydrochloride (2 μg/mL).
RESULTS: Puromycin dihydrochloride screened and maintained lentivirally successfully transfected cells. [3]

Puromycin is utilized to select recombinant cells from non-cultured cells. It serves as a tool for studying protein synthesis in many systems.